Adverse reactions associated with theophylline are generally mild when peak serum theophylline concentrations are <20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum theophylline concentrations exceed 20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see OVERDOSAGE).
Other adverse reactions that have been reported at serum theophylline concentrations <20 mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum theophylline concentrations ≥15 mcg/mL. There have been a few isolated reports of seizures at serum theophylline concentrations <20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of seizures in elderly patients with serum theophylline concentrations <20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum theophylline concentrations <20 mcg/mL have generally been milder than seizures associated with excessive serum theophylline concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).
Products containing aminophylline may rarely produce severe allergic reactions of the skin, including exfoliative dermatitis, after systemic administration in a patient who has been previously sensitized by topical application of a substance containing ethylenediamine. In such patients skin patch tests are positive for ethylenediamine, a component of aminophylline, and negative for theophylline. Pharmacists and other individuals who experience repeated skin exposure while physically handling aminophylline may develop a contact dermatitis due to the ethylenediamine component.
* These data are derived from two studies in patients with serum theophylline concentrations >30 mcg/mL. In the first study (Study #1 – Shanon, Ann Intern Med 1993;119:1161-67), data were prospectively collected from 249 consecutive cases of theophylline toxicity referred to a regional poison center for consultation. In the second study (Study #2 – Sessler, Am J Med 1990; 88:567-76), data were retrospectively collected from 116 cases with serum theophylline concentrations >30 mcg/mL among 6000 blood samples obtained for measurement of serum theophylline concentrations in three emergency departments. Differences in the incidence of manifestations of theophylline toxicity between the two studies may reflect sample selection as a result of study design (e.g., in Study #1, 48% of the patients had acute intoxications versus only 10% in Study #2) and different methods of reporting results. ** NR = Not reported in a comparable manner. | ||||||||
Acute Overdose (Large Single Ingestion) | Chronic Overdosage (Multiple Excessive Doses) | |||||||
Sign/Symptom | Study 1 (n=157) | Study 2 (n=14) | Study 1 (n=92) | Study 2 (n=102) | ||||
Asymptomatic | NR** | 0 | NR** | 6 | ||||
Gastrointestinal | ||||||||
Vomiting | 73 | 93 | 30 | 61 | ||||
Abdominal pain | NR** | 21 | NR** | 12 | ||||
Diarrhea | NR** | 0 | NR** | 14 | ||||
Hematemesis | NR** | 0 | NR** | 2 | ||||
Metabolic/Other | ||||||||
Hypokalemia | 85 | 79 | 44 | 43 | ||||
Hyperglycemia | 98 | NR** | 18 | NR** | ||||
Acid/base disturbance | 34 | 21 | 9 | 5 | ||||
Rhabdomyolysis | NR** | 7 | NR** | 0 | ||||
Cardiovascular | ||||||||
Sinus tachycardia | 100 | 86 | 100 | 62 | ||||
Other supraventricular | 2 | 21 | 12 | 14 | ||||
tachycardias | ||||||||
Ventricular premature beats | 3 | 21 | 10 | 19 | ||||
Atrial fibrillation or flutter | 1 | NR** | 12 | NR** | ||||
Multifocal atrial tachycardia | 0 | NR** | 2 | NR** | ||||
Ventricular arrhythmias with | 7 | 14 | 40 | 0 | ||||
hemodynamic instability | ||||||||
Hypotension/shock | NR** | 21 | NR** | 8 | ||||
Neurologic | ||||||||
Nervousness | NR** | 64 | NR** | 21 | ||||
Tremors | 38 | 29 | 16 | 14 | ||||
Disorientation | NR** | 7 | NR** | 11 | ||||
Seizures | 5 | 14 | 14 | 5 | ||||
Death | 3 | 21 | 10 | 4 |
Adverse reactions associated with theophylline are generally mild when peak serum theophylline concentrations are <20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum theophylline concentrations exceed 20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see OVERDOSAGE).
Other adverse reactions that have been reported at serum theophylline concentrations <20 mcg/mL include diarrhea, irritability, restlessness, fine skeletal muscle tremors, and transient diuresis. In patients with hypoxia secondary to COPD, multifocal atrial tachycardia and flutter have been reported at serum theophylline concentrations ≥15 mcg/mL. There have been a few isolated reports of seizures at serum theophylline concentrations <20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of seizures in elderly patients with serum theophylline concentrations <20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. The clinical characteristics of the seizures reported in patients with serum theophylline concentrations <20 mcg/mL have generally been milder than seizures associated with excessive serum theophylline concentrations resulting from an overdose (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).
Products containing aminophylline may rarely produce severe allergic reactions of the skin, including exfoliative dermatitis, after systemic administration in a patient who has been previously sensitized by topical application of a substance containing ethylenediamine. In such patients skin patch tests are positive for ethylenediamine, a component of aminophylline, and negative for theophylline. Pharmacists and other individuals who experience repeated skin exposure while physically handling aminophylline may develop a contact dermatitis due to the ethylenediamine component.
* These data are derived from two studies in patients with serum theophylline concentrations >30 mcg/mL. In the first study (Study #1 – Shanon, Ann Intern Med 1993;119:1161-67), data were prospectively collected from 249 consecutive cases of theophylline toxicity referred to a regional poison center for consultation. In the second study (Study #2 – Sessler, Am J Med 1990; 88:567-76), data were retrospectively collected from 116 cases with serum theophylline concentrations >30 mcg/mL among 6000 blood samples obtained for measurement of serum theophylline concentrations in three emergency departments. Differences in the incidence of manifestations of theophylline toxicity between the two studies may reflect sample selection as a result of study design (e.g., in Study #1, 48% of the patients had acute intoxications versus only 10% in Study #2) and different methods of reporting results. ** NR = Not reported in a comparable manner. | ||||||||
Acute Overdose (Large Single Ingestion) | Chronic Overdosage (Multiple Excessive Doses) | |||||||
Sign/Symptom | Study 1 (n=157) | Study 2 (n=14) | Study 1 (n=92) | Study 2 (n=102) | ||||
Asymptomatic | NR** | 0 | NR** | 6 | ||||
Gastrointestinal | ||||||||
Vomiting | 73 | 93 | 30 | 61 | ||||
Abdominal pain | NR** | 21 | NR** | 12 | ||||
Diarrhea | NR** | 0 | NR** | 14 | ||||
Hematemesis | NR** | 0 | NR** | 2 | ||||
Metabolic/Other | ||||||||
Hypokalemia | 85 | 79 | 44 | 43 | ||||
Hyperglycemia | 98 | NR** | 18 | NR** | ||||
Acid/base disturbance | 34 | 21 | 9 | 5 | ||||
Rhabdomyolysis | NR** | 7 | NR** | 0 | ||||
Cardiovascular | ||||||||
Sinus tachycardia | 100 | 86 | 100 | 62 | ||||
Other supraventricular | 2 | 21 | 12 | 14 | ||||
tachycardias | ||||||||
Ventricular premature beats | 3 | 21 | 10 | 19 | ||||
Atrial fibrillation or flutter | 1 | NR** | 12 | NR** | ||||
Multifocal atrial tachycardia | 0 | NR** | 2 | NR** | ||||
Ventricular arrhythmias with | 7 | 14 | 40 | 0 | ||||
hemodynamic instability | ||||||||
Hypotension/shock | NR** | 21 | NR** | 8 | ||||
Neurologic | ||||||||
Nervousness | NR** | 64 | NR** | 21 | ||||
Tremors | 38 | 29 | 16 | 14 | ||||
Disorientation | NR** | 7 | NR** | 11 | ||||
Seizures | 5 | 14 | 14 | 5 | ||||
Death | 3 | 21 | 10 | 4 |
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.